MSU
CLVS

Mizuho Securities USA’s Clovis Oncology, Inc. CLVS Stock Holding History

Mizuho Securities USA’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-10,500
Closed -$261K – 155
2019
Q1 		$261K Buy
+10,500
New +$263K 0.02% 98

Other funds holding CLVS

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Mizuho Securities USA's CLVS Position: Q2 2019 in Review

Mizuho Securities USA sold out of Clovis Oncology, Inc. (CLVS) in Q2 2019, closing a stake of 10,500 shares — an estimated $261K sold.

Mizuho Securities USA first reported a position in CLVS in Q1 2019 and held it in 1 quarter. The position peaked at $261K in Q1 2019. 167 funds tracked by Wall St. Rank hold CLVS as of Q2 2019.

  • Mizuho Securities USA reported no remaining Clovis Oncology, Inc. position as of Q2 2019 after selling out during the quarter.
  • Mizuho Securities USA sold 10,500 Clovis Oncology, Inc. shares in Q2 2019, an estimated $261K.
  • Mizuho Securities USA first reported a position in Clovis Oncology, Inc. in Q1 2019 and held it in 1 quarter.
  • Mizuho Securities USA's Clovis Oncology, Inc. position peaked at $261K in Q1 2019.
  • 167 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q2 2019.

Based on Mizuho Securities USA's 13F filing for Q2 2019, filed 8 Aug 2019.